Aurigene will present data on its potent and selective CDK7 novel covalent inhibitor program and KRAS covalent inhibitor targeting G12C mutations – Both of these programs are currently in Lead Optimization.

Additional information on the presentations can be found below and abstracts can be accessed at


KRAS G12C Covalent Inhibitors

Title: Identification of novel covalent inhibitors of KRAS G12C that are efficacious in a xenograft model of NSCLC

Session ID:                                        Poster Section 17

Session Category:                            Experimental and Molecular Therapeutics

Session Title:                                    Novel Antitumor Agents

Session Date and Time:                 Sunday Apr 17, 2016 1:00 PM – 5:00 PM

Location:                                           Convention Center, Halls G-J, Poster Section 17

Permanent Abstract Number:      339


Selective CDK7 Covalent Inhibitors

Title: Potent and selective inhibition of CDK7 by novel covalent inhibitors

Session ID:                                          Poster Section 19

Session Category:                              Experimental and Molecular Therapeutics

Session Title:                                      Small Molecule Inhibitors

Session Date and Time:                   Tuesday Apr 19, 2016 8:00 AM – 12:00 PM

Location:                                             Convention Center, Halls G-J, Poster Section 19

Permanent Abstract Number:        3070

About Aurigene

Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene’s Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has signed four licensing deals in the last couple of years. Aurigene is currently seeking partners for its current pipeline of advanced assets (a) RORg for autoimmune diseases which is in preclinical development (b) Novel NAMPT inhibitors for niche cancers, also in preclinical development (c) Covalent CDK7 and KRAS small molecule programs that are currently in lead optimization. For more information about Aurigene and our pipeline, please visit Aurigene’s website at


Media Contact:

Rajshree KT

Director Corporate Development & Strategy

+91 – 40 – 4465 7777